|
|
 |
|
| Overview |
| CD90 was developed for the positive selection or depletion of cells expressing human CD90 antigen, e.g., liver cancer stem cells from single cell suspensions from solid tumors or cancer cell lines. |
| Details |
Background information
The CD90 antibody reacts with the human CD90 antigen, also known as Thy-1. CD90 was identified as a marker for cancer stem cells in human liver cancer1. In addition to cancer stem cells, it is expressed on embryonic stem cells (ESC), induced pluripotent stem cells (iPSC), neurons, small subsets of human fetal liver cells and thymocytes, cord blood and bone marrow cells. CD90 is also expressed on a subset of CD34+ primitive hematopoietic stem cells. CD90+CD34+ cells characterize a highly enriched population of high proliferative potential colony-forming cells (HPP-CFC)2. Furthermore, CD90 expression is found on mesenchymal stem cells (MSCs)3. |
| Columns |
| For postive selection: MS, LS, or autoMACS Columns. For depletion: LD or autoMACS Columns. |
| |
|
| CD90+ human teratocarcinoma cells (NTERA2) were isolated from a mixture of U937 and NTERA2 cells using CD90 MicroBeads, an MS Column, and an OctoMACS™ Separator. Cells were fluorescently stained with CD90-PE (# 130-095-400) and CD326 (EpCAM)-APC (# 130-091-254) and analyzed by flow cytometry using the MACSQuant® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence. |
| Before separation |
 |
| CD90+ cells |
 |
|
|
|
|
| Favorites / Prices |
Request prices or add products to your favorite list.
|
| Details |
|
| References |
| 1. Zhen Fan Yang, Z. F. et al. (2008) Cancer Cell 13: 153–166. |
| 2. Mayani, H. and Lansdorp, P. M. (1994) Blood 83: 2410–2417. |
| 3. Dominici, M. et al. (2006) Cytotherapy 8: 315–317. |
|
|
|
© 1999 - 2012 Miltenyi Biotec ¦ Terms & conditions ¦ Legal notes
|
